China bladder cancer market is estimated to grow modestly at a CAGR of around 10.1% during the forecast period. The country has a strong healthcare industry and is continuously developing medical facilities and research centers to improve the industry further. Bladder cancer is one of the major cancers diagnosed in the elderly population of the country. The growing prevalence of bladder cancer in the country is attributed to growth in the aging population and a rapid increase in the number of smokers. Cancer is one of the leading causes of mortality in China. According to WHO, China has reported a total of 82,270 new cases of bladder cancer in 2018 out of which 38,208 cases resulted in mortality. As per the organization, China accounts for 222,292 bladder cancer patients in the last 5 years. Due to increasing industrialization in the country, harmful chemicals are being ejected into the atmosphere and chemical exposure is one of the major causes of bladder cancer. Therefore, with rapid industrialization in the country, China is estimated to contribute substantially to the global bladder cancer market during the forecast period.
To Request a Sample of our Report on China Bladder Cancer Market: https://www.omrglobal.com/request-sample/china-bladder-cancer-market
China bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
(Get 15% Discount on Buying this Report)
A full Report of China Bladder Cancer Market is Available at: https://www.omrglobal.com/request-sample/china-bladder-cancer-market
China Bladder Cancer Market Segmentation
By Cancer Type
· Transitional Cell Bladder Cancer/ Urothelial Carcinoma
· Squamous Cell Bladder Cancer
· Adenocarcinoma
· Others (Sarcomas, Carcinoma in Situ)
By Diagnosis
· Cystoscopy
· Biopsy
· Urinalysis
· Urine Cytology
· Intravenous Pyelogram (IVP)
· Others (Biomarkers)
By Treatment
· Surgery
· Chemotherapy
· Immunotherapy
· Radiation Therapy
· Others (Targeted Therapy)
Company Profiles
· Astellas Pharma Inc.
· AstraZeneca PLC
· Bayer AG
· Bristol-Myers Squibb Co.
· Eli Lilly and Co.
· F. Hoffmann-La Roche AG
· GlaxoSmithKline Plc
· Johnson & Johnson Services, Inc.
· Merck KGaA
· Pfizer Inc.
· Sysmex Corp.
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
